Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 18/20 | 0.83 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | PDE6C | P51160 | 2/20 | 0.51 |
| ▸ | PDE11A | Q9HCR9 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6290660 | 0.91 | PDE5A (1.00) | PDE5A | |
| SCHEMBL6407260 | 0.91 | PDE5A (1.00) | PDE5A | |
| SCHEMBL6409670 | 0.91 | PDE5A (1.00) | PDE5A | |
| SCHEMBL28392937 | 0.84 | PDE5A (1.00) | PDE5APDE6CPDE11A | |
| SCHEMBL28395133 | 0.84 | PDE5A (0.78) | PDE5APDE6CPDE11A | |
| SCHEMBL6413069 | 0.81 | PDE5A (1.00) | PDE5A | |
| SCHEMBL6406398 | 0.81 | PDE5A (1.00) | PDE5A | |
| SCHEMBL6406296 | 0.78 | PDE5A (1.00) | PDE5A | |
| SCHEMBL6407670 | 0.78 | PDE5A (1.00) | PDE5A | |
| SCHEMBL6409674 | 0.78 | PDE5A (1.00) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113402-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | SUI ZHIHUA (US) | 2005-05-26 | — | — | US | disclosed |
| EP-1296981-B1 | SUBSTITUTED PYRROLOPYRIDINONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20020072055-A1 | Iterative and regenerative DNA sequencing method | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2002-06-13 | — | — | US | disclosed |
| US-20020010183-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113402-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | PDE5A 1/4885ABCB1 1507/4885ABCG2 2481/4885 |
| US-20020010183-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | PDE5A 1/4885ABCB1 1581/4885ABCG2 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.